May 4, 2016




U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549


Attn: Suzanne Hayes
Re: Oncobiologics, Inc.
  Registration Statement on Form S-1
  File No. 333-209011


  Acceleration Request  
  Requested Date: May 5, 2016
  Requested Time: 4:00 p.m., Eastern Time


Ladies and gentlemen:


In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Jefferies LLC and Barclays Capital Inc., as representatives of the several underwriters, hereby join Oncobiologics, Inc. in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-209011) to become effective on Thursday, May 5, 2016, at 4:00 p.m., Eastern Time, or as soon as practicable thereafter.


Additionally, pursuant to Rule 460 of the Act, we hereby advise you that the Preliminary Prospectus dated April 27, 2016, was distributed by us, as representatives of the several underwriters, approximately as follows from April 27, 2016 through the date hereof:


Copies to underwriters 661
Copies to dealers 0
Copies to institutional investors 588
Copies to others/retail 5
Total 1,254


We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.


Very truly yours,




As Representatives


[Signature Page Follows]





  By: /s/ Matthew Kim
    Name: Matthew Kim
    Title:   Managing Director
  By: /s/ Victoria Hale
    Name: Victoria Hale
    Title:   Vice President


cc: Pankaj Mohan, Ph.D., Oncobiologics, Inc.
  Lawrence A. Kenyon, Oncobiologics, Inc.
  Stuart M. Cable, Goodwin Procter LLP
  Edwin O’Connor, Goodwin Procter LLP
  Seo Salimi, Goodwin Procter LLP
  Yvan-Claude Pierre, Cooley LLP
  Daniel I. Goldberg, Cooley LLP
  Marianne Sarrazin, Cooley LLP


[signature page to acceleration request letter]